RxDoctor Payments Data

Amy Blanchard, MD

Sleep Medicine · Augusta, GANPI 1538279245

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,845 of the $3,351 with a category attached, or 84.9%. 7 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 54.7% of the total. Reporting peaked in 2023 at $1,105 and has fallen 67.2% since, to $363 in 2025.

$3,351in general payments, 2019–2025

Across 68 payments — averaging $49.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$2K
  • Jazz Pharmaceuticals Inc.$667
  • Harmony Biosciences LLC$523
  • Axsome Therapeutics, Inc.$230
  • Inari Medical, Inc.$51
  • Avadel CNS Pharmaceuticals, LLC$24
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$2,84585%
  • Education$50615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,351 in reported general payments places this provider in the 70th percentile of 50 sleep medicine providers in Georgia.

See all sleep medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$34,430
Medicare patients
319
Services billed
477

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate11$190,497
WakixPitolisant Hcl11$173,184
BelsomraSuvorexant17$10,571
Spiriva HandihalerTiotropium Bromide12$6,184
Breo ElliptaFluticasone/Vilanterol11$4,841
SymbicortBudesonide/Formoterol Fumarate15$3,509
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,542
Modafinil37$1,812
Zolpidem Tartrate ErZolpidem Tartrate33$1,757
Albuterol Sulfate HfaAlbuterol Sulfate50$1,155
Azelastine Hcl18$754
Trazodone Hcl103$689
Doxepin Hcl13$528
Ropinirole Hcl22$464
Clonazepam22$399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$523$173,18411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 50 sleep medicine providers in Georgia.

Other sleep medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →